File downloaded on 2026-11-20
Source URL: https://medicines.health.europa.eu/veterinary/en/600000032834

CANIGEN L SUSPENSION FOR INJECTION FOR DOGS

Authorised

- Leptospira interrogans, serovar Canicola, strain 601903, Inactivated
- Leptospira interrogans, serovar Icterohaemorrhagiae, strain 601895, Inactivated

Product identification

Medicine name:
CANIGEN L SUSPENSION FOR INJECTION FOR DOGS

Active substance:
Leptospira interrogans, serovar Canicola, strain 601903, Inactivated

Leptospira interrogans, serovar Icterohaemorrhagiae, strain 601895, Inactivated

Target species:
Dog

Route of administration:
Subcutaneous use

Product details

Active substance and strength:
Leptospira interrogans, serovar Canicola, strain 601903, Inactivated
4350.00 enzyme-linked immunosorbent assay unit / 1.00 millilitre(s)

Leptospira interrogans, serovar Icterohaemorrhagiae, strain 601895, Inactivated
4250.00 enzyme-linked immunosorbent assay unit / 1.00 millilitre(s)

Pharmaceutical form:
Suspension for injection

Anatomical therapeutic chemical veterinary (ATCvet) codes:
QI07AB01

Legal status of supply:
Veterinary medicinal product subject to veterinary prescription

Authorisation status:
Valid

Authorised in:
Germany

Available in:
Germany

Package description:
Plastic box of 1 vial containing 1 ml of suspension
Plastic box of 100 vials containing 1 ml of suspension
Plastic box of 50 vials containing 1 ml of suspension
Plastic box of 25 vials containing 1 ml of suspension
Plastic box of 10 vials containing 1 ml of suspension
Cardboard box of 1 vial containing 1 ml of suspension
Cardboard box of 100 vials containing 1 ml of suspension
Cardboard box of 50 vials containing 1 ml of suspension
Cardboard box of 25 vials containing 1 ml of suspension
Cardboard box of 10 vials containing 1 ml of suspension

Additional information

Entitlement type:
Marketing Authorisation

Legal basis of product authorisation:

Full application - Known active substance (Article 12(3) of Directive No 2001/82/EC)

Marketing authorisation holder:
Virbac

Marketing authorisation date:
3/04/2017

Manufacturing sites for batch release:
Virbac

Responsible authority:
Paul-Ehrlich-Institut

Authorisation number:
PEI.V.11853.01.1

Date of authorisation status change:
3/04/2017

Reference member state:
France

Procedure number:
FR/V/0310/001

Concerned member states:
Austria Belgium Bulgaria Croatia Cyprus Czechia Denmark Estonia Germany Greece Hungary Ireland Italy Latvia Lithuania Luxembourg Netherlands Poland Portugal Romania Slovakia Slovenia Spain Sweden United Kingdom (Northern Ireland)

To consult adverse reactions on veterinary medicinal products please go to www.adrreports.eu/vet

Documents

Combined File of all Documents

English (PDF)
Published on: 14/03/2026
Download

eu-puar-frv0310001-mr-rpe293-en.pdf